WallStSmart

Insmed Inc (INSM)vsLisata Therapeutics Inc. (LSTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 356619% more annual revenue ($606.42M vs $170,000). LSTA leads profitability with a 0.0% profit margin vs -2.1%. INSM appears more attractively valued with a PEG of 1.09. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

LSTA

Avoid

17

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

LSTA1 strengths · Avg: 8.0/10
Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

LSTA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$45.34M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

PEG RatioValuation
118.402/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : LSTA

The strongest argument for LSTA centers on Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : LSTA

The primary concerns for LSTA are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while LSTA is a value play — different risk/reward profiles.

LSTA carries more volatility with a beta of 1.27 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

LSTA generates stronger free cash flow (-3M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 17/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Lisata Therapeutics Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.

Want to dig deeper into these stocks?